Navigation Links
New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease
Date:4/26/2012

dicines/human/medicines/000626/human_med_000926.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124

For further information
Andrea Levin, Associate Director, Public Relations and Communications, UCB
T +1.770.970.8352, andrea.levin@ucb.com      

Eimear O'Brien, Director, Brand Communications, UCB
T +32.2.559.9271, eimear.obrien@ucb.com

Antje Witte, Investor Relations, UCB
T +32.2.559.9414,
antje.witte@ucb.com

France Nivelle, Global Communications, UCB
T +32.2.559.9178,
france.nivelle@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks,
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
2. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
3. New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response
4. Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
5. First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies
6. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
7. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
8. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
9. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
10. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
11. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Mass. , July 24, 2014   ndd ... function testing (PFT) employing precise ultrasound technology, announced that ... the instrument to measure Carbon Monoxide Diffusing Capacity (DLCO) ... the most comprehensive study of Chronic Obstructive Pulmonary Disease ... cause of death in the U.S. and affects millions ...
(Date:7/23/2014)... N.Y. , July 23, 2014 ... of idelalisib to treat patients with relapsed chronic ... lymphocytic lymphoma (SLL) is a significant advance for ... Idelalisib, which goes by the trade name Zydelig®, ... protein that is highly expressed in many B-cell ...
(Date:7/23/2014)... MOUNTAIN VIEW, Calif. , July 23, 2014 ... translational preclinical research, today unveiled their new logo and ... transformation of Surpass, corporate culture to one where our ... This press release comes on the heels of the ... to the Silicon Valley Team:  David Craig, a veteran ...
Breaking Medicine Technology:EasyOne Pro from ndd Medical Technologies Chosen Again as the Exclusive PFT Testing Technology in Phase 2 of COPDGene Study 2The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... Feb. 15 Intra-Cellular Therapies, Inc. (ITI),announced ... its,first-in-class dual 5HT2A receptor antagonist/dopamine receptor,phosphoprotein modulator ... ITI,s family of compounds that inhibit a ... dysfunction in schizophrenia. Data,characterizing the pharmacological profile ...
... Plan Also Calls for Expansion of Business Development, Streamlining of ... ... Conference Call/Webcast at 11 a.m. EST Today -, LA JOLLA, Calif., ... strategic plan for 2008 with a focus,on clinical development activities to maximize ...
Cached Medicine Technology:Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 2Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 3Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 4TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 2TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 3TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 4TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 5TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 6
(Date:7/24/2014)... July 24, 2014 A new report ... nearly 80 percent of doctors in the U.S. have upgraded ... year. , Doctors appear to be embracing more digital options. ... time, linking them to past patient histories, the latest published ... physician. , A report from the Robert Wood Johnson ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Representatives from ... be on hand to provide educational and support resources ... Meeting next week in Colorado Springs. , The Annual ... of the most renowned neurointerventional research centers ... and innovating together (with or at) symposiums, physician meetings, ...
(Date:7/24/2014)... The Arm Lift, also known as brachioplasty, is ... from the upper arms to create a more toned, slimmed ... can become lax and may begin to sag, resulting in ... appearance of sagging upper arms, and seek treatment to restore ... is now offering brachioplasty to tighten and improve the contours ...
(Date:7/24/2014)... Colo. (PRWEB) July 24, 2014 ... Prepared to Identify and Prevent the Three Infections ... Infections?’ is a go-to guide to help ... risk factors and details basic prevention measures that ... The e-book is available for download at ...
(Date:7/24/2014)... 24, 2014 The Republic of Tea, leading ... CARDAMOM CRÈME BRÛLÉE TEA to celebrate “The Hundred-Foot Journey,” a ... and Juliet Blake. A hundred-foot journey begins in the moment ... into a new realm that is far out of your ... physical distance that materially changes the course of your life ...
Breaking Medicine News(10 mins):Health News:Doctors Embracing Changing Technologies, And Technology Brings Options to Treatment 2Health News:Doctors Embracing Changing Technologies, And Technology Brings Options to Treatment 3Health News:Brain Aneurysm Foundation Provides Key Support to NeuroIntervential Physicians 2Health News:How to Get Toned Arms With Arm Lift Procedure 2Health News:How to Get Toned Arms With Arm Lift Procedure 3Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 2Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 3Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 2Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 3
... , WEDNESDAY, Dec. 8 (HealthDay News) -- ... of developing several invasive bacterial diseases, according to a ... found to be especially strong for children 6 years ... the risk for invasive meningococcal disease, the analysis found, ...
... 8, 2010) Jeffrey S. Upperman, MD, director of ... a call to action for filling a significant gap in ... the framework for a pediatric applied trauma research network (PATRN). ... Journal of Pediatric Surgery and the Journal ...
... breakthrough? See what the experts have to say ... Perspectives on Psychological Science . Neuroimaging: ... Special Section on fMRI ( http://pps.sagepub.com/content/5/6/714.full ) ... widespread interest following the publication of Vul et ...
... , WEDNESDAY, Dec. 8 (HealthDay News) -- The children ... pregnancy are less likely to develop atopic dermatitis in their ... Atopic dermatitis (also called atopic eczema) is a chronic and ... The condition affects up to 20 percent of children in ...
... , WEDNESDAY, Dec. 8 (HealthDay News) -- A new ... blood to scan the genome of a fetus may offer ... genetic diseases, a new study suggests. Currently, a sample ... amniocentesis or chorionic villus sampling, both of which pose a ...
... ANN ARBOR, Mich. Patients who have complications after ... even when it is clearly recommended for their diagnosis, ... Cancer Center finds. In addition, patients with complications ... chemotherapy delayed for more than 120 days after diagnosis ...
Cached Medicine News:Health News:Trauma surgeon leads call to action for pediatric applied trauma research network 2Health News:fMRI special section of Perspectives on Psychological Science 2Health News:fMRI special section of Perspectives on Psychological Science 3Health News:Surgery complications linked to chemotherapy delay, U-M study finds 2
Each handle is designed to fit a specific trephine size....
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
Medicine Products: